Patents by Inventor Phillip W. Berman
Phillip W. Berman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20200231633Abstract: Mannosyl (alpha-1,3)-glycoprotein beta-1,2-N-Acetylglucosaminyltransferase (Mgat1)-deficient cell lines and methods for use of same for producing human immunodeficiency virus (HIV) envelope glycoprotein polypeptides or fragment thereof with terminal mannose-5 glycans are provided.Type: ApplicationFiled: July 16, 2018Publication date: July 23, 2020Inventors: Phillip W. Berman, Gabriel Byrne
-
Patent number: 7264817Abstract: Disclosed is an invention related to the preparation and use of vaccines against pathogenic organisms, such as herpes virus. The vaccines hereof are based upon the use of truncated, membrane-free derivatives of a membrane-bound polypeptide from the pathogen. These polypeptides when incorporated into a vaccine composition afford protection against pathogenic challenge after administration.Type: GrantFiled: June 2, 1995Date of Patent: September 4, 2007Assignee: Genentech, Inc.Inventors: Phillip W. Berman, Laurence A. Lasky
-
Patent number: 7071322Abstract: Oligonucleotide sequences encoding gp120 polypeptides from breakthrough isolates of vaccine trials using MN-rgp120 and the encoded gp120 polypeptides are provided. Use of the gp120 polypeptides from one or more of the isolates in a subunit vaccine, usually together with MN-rgp120, can provide protection against HIV strains that are sufficiently different from the vaccine strain (e.g.; MN-rgp120) that the vaccine does not confer protection against those strains. Antibodies induced by the polypeptides are also provided.Type: GrantFiled: February 21, 2003Date of Patent: July 4, 2006Assignee: Genentech, Inc.Inventor: Phillip W. Berman
-
Patent number: 7041293Abstract: The invention provides antibodies specific for HIV env, including monoclonal antibodies and related hybridomas. The antibodies block CD4/g120 binding and reduce reverse transcriptase activity in vitro.Type: GrantFiled: June 23, 1998Date of Patent: May 9, 2006Assignee: Genentech, Inc.Inventors: Phillip W. Berman, Brian M. Fendly, Timothy J. Gregory, Florian M. Wurm
-
Patent number: 6806055Abstract: A method for the rational design and preparation of vaccines based on HIV envelope polypeptides is described. In one embodiment, the method for making an HIV gp120 subunit vaccine for a geographic region comprises determining neutralizing epitopes in the V2 and/or C4 domains of gp120 of HIV isolates from the geographic region and selecting an HIV strain having gp120 a neutralizing epitope in the V2 or C4 domain which is common among isolates in the geographic region. In a preferred embodiment of the method, neutralizing epitopes for the V2, V3, and C4 domains of gp120 are determined. At least two HIV isolates having different neutralizing epitopes in the V2, V3, or C4 domain are selected and used.to make the vaccine. The invention also provides a multivalent HIV gp120 subunit vaccine.Type: GrantFiled: September 27, 2001Date of Patent: October 19, 2004Assignee: Genentech, Inc.Inventors: Phillip W. Berman, Gerald R. Nakamura
-
Publication number: 20040121317Abstract: A method for the rational design and preparation of vaccines based on HIV envelope polypeptides is described. In one embodiment, the method for making an HIV gp120 subunit vaccine for a geographic region comprises determining neutralizing epitopes in the V2 and/or C4 domains of gp120 of HIV isolates from the geographic region and selecting an HIV strain having gp120 a neutralizing epitope in the V2 or C4 domain which is common among isolates in the geographic region. In a preferred embodiment of the method, neutralizing epitopes for the V2, V3, and C4 domains of gp120 are determined. At least two HIV isolates having different neutralizing epitopes in the V2, V3, or C4 domain are selected and used to make the vaccine. The invention also provides a multivalent HIV gp120 subunit vaccine.Type: ApplicationFiled: June 10, 2003Publication date: June 24, 2004Applicant: Genentech, Inc.Inventors: Phillip W. Berman, Gerald R. Nakamura
-
Publication number: 20040077013Abstract: DNA constructs, host cells and production methods are disclosed for the expression and recovery of polypeptides, especially those altered to have one or more glycosylation sites added or deleted. The DNA constructs, host cells and methods provided herein employ a DNA segment corresponding to a mammalian tissue plasminogen activator signal and/or pro peptide.Type: ApplicationFiled: October 15, 2003Publication date: April 22, 2004Applicant: Genentech, Inc.Inventors: Avi J. Ashkenazi, Phillip W. Berman, David Brousseau, Tina Etcheverry
-
Publication number: 20040052821Abstract: Oligonucleotide sequences encoding gp120 polypeptides from breakthrough isolates of vaccine trials using MN-rgp120 and the encoded gp120 polypeptides are provided. Use of the gp120 polypeptides from one or more of the isolates in a subunit vaccine, usually together with MN-rgp120, can provide protection against HIV strains that are sufficiently different from the vaccine strain (e.g.; MN-rgp120) that the vaccine does not confer protection against those strains. Antibodies induced by the polypeptides are also provided.Type: ApplicationFiled: February 21, 2003Publication date: March 18, 2004Applicant: Genentech, Inc.Inventor: Phillip W. Berman
-
Patent number: 6693181Abstract: DNA constructs, host cells and production methods are disclosed for the expression and recovery of polypeptides, especially those altered to have one or more glycosylation sites added or deleted. The DNA constructs, host cells and methods provided herein employ a DNA segment corresponding to a mammalian tissue plasminogen activator signal and/or pro peptide.Type: GrantFiled: April 14, 1999Date of Patent: February 17, 2004Assignee: Genentech, Inc.Inventors: Avi J. Ashkenazi, Phillip W. Berman, David Brousseau, Tina Etcheverry
-
Publication number: 20040014172Abstract: Diagnostic product and vaccine for Acquired Immuno-deficiency Syndrome (AIDS) and methods for making and using same, wherein viral polypeptide sequences from an AIDS associated retrovirus are expressed directly or as a fusion polypeptide in a prokaryotic or mammalian cell expression host to produce a diagnostic product which specifically binds complementary antibody produced by individuals afflicted with AIDS or a vaccine against AIDS which confers resistance to infection by AIDS associated retrovirus. The reverse transcriptase of an AIDS associated retrovirus is used separately or in a whole cell assay to identify compounds which selectively inhibit retroviral reverse transcriptase.Type: ApplicationFiled: March 7, 2003Publication date: January 22, 2004Applicant: Genentech, Inc.Inventors: Phillip W. Berman, Daniel J. Capon, Laurence A. Lasky
-
Patent number: 6585979Abstract: Oligonucleotide sequences encoding gp120 polypeptides from breakthrough isolates of vaccine trials using MN-rgp120 and the encoded gp120 polypeptides are provided. Use of the gp120 polypeptides from one or more of the isolates in a subunit vaccine, usually together with MN-rgp120, can provide protection against HIV strains that are sufficiently different from the vaccine strain (e.g.; MN-rgp120) that the vaccine does not confer protection against those strains. Antibodies induced by the polypeptides are also provided.Type: GrantFiled: October 15, 1999Date of Patent: July 1, 2003Assignee: Genentech, Inc.Inventor: Phillip W. Berman
-
Publication number: 20030064361Abstract: A method for the rational design and preparation of vaccines based on HIV envelope polypeptides is described. In one embodiment, the method for making an HIV gp120 subunit vaccine for a geographic region comprises determining neutralizing epitopes in the V2 and/or C4 domains of gp120 of HIV isolates from the geographic region and selecting an HIV strain having gp120 a neutralizing epitope in the V2 or C4 domain which is common among isolates in the geographic region. In a preferred embodiment of the method, neutralizing epitopes for the V2, V3, and C4 domains of gp120 are determined. At least two HIV isolates having different neutralizing epitopes in the V2, V3, or C4 domain are selected and used to make the vaccine. The invention also provides a multivalent HIV gp120 subunit vaccine.Type: ApplicationFiled: September 27, 2001Publication date: April 3, 2003Applicant: Genentech, Inc.Inventors: Phillip W. Berman, Gerald R. Nakamura
-
Patent number: 6534285Abstract: Diagnostic product and vaccine for Acquired Immuno-deficiency Syndrome (AIDS) and methods for making and using same, wherein viral polypeptide sequences from an AIDS associated retrovirus are expressed directly or as a fusion polypeptide in a prokaryotic or mammalian cell expression host to produce a diagnostic product which specifically binds complementary antibody produced by individuals afflicted with AIDS or a vaccine against AIDS which confers resistance to infection by AIDS associated retrovirus. The reverse transcriptase of an AIDS associated retrovirus is used separately or in a whole cell assay to identify compounds which selectively inhibit retroviral reverse transcriptase.Type: GrantFiled: April 12, 2000Date of Patent: March 18, 2003Assignee: Genentech, Inc.Inventors: Phillip W. Berman, Daniel J. Capon, Laurence A. Lasky
-
Publication number: 20020155525Abstract: DNA constructs, host cells and production methods are disclosed for the expression and recovery of polypeptides, especially those altered to have one or more glycosylation sites added or deleted. The DNA constructs, host cells and methods provided herein employ a DNA segment corresponding to a mammalian tissue plasminogen activator signal and/or pro peptide.Type: ApplicationFiled: April 14, 1999Publication date: October 24, 2002Inventors: AVI J. ASHKENAZI, PHILLIP W. BERMAN, DAVID BROUSSEAU, TINA ETCHEVERRY
-
Patent number: 6331404Abstract: A method for the rational design and preparation of vaccines based on HIV envelope polypeptides is described. In one embodiment, the method for making an HIV gp120 subunit vaccine for a geographic region comprises determining neutralizing epitopes in the V2 and/or C4 domains of gp120 of HIV isolates from the geographic region and selecting an HIV strain having gp120 a neutralizing epitope in the V2 or C4-domain which is common among isolates in the geographic region. In a preferred embodiment of the method, neutralizing epitopes for the V2, V3, and C4 domains of gp120 are determined. At least two HIV isolates having different neutralizing epitopes in the V2, V3, or C4 domain are selected and used to make the vaccine. The invention also provides a multivalent HIV gp120 subunit vaccine.Type: GrantFiled: January 27, 2000Date of Patent: December 18, 2001Assignee: Genentech, Inc.Inventors: Phillip W. Berman, Gerald R. Nakamura
-
Patent number: 6090392Abstract: Oligonucleotide sequences encoding gp120 polypeptides from breakthrough isolates of vaccine trials using MN-rgp120 and the encoded gp120 polypeptides are provided. Use of the gp120 polypeptides from one or more of the isolates in a subunit vaccine, usually together with MN-rgp120, can provide protection against HIV strains that are sufficiently different from the vaccine strain (e.g.; MN-rgp120) that the vaccine does not confer protection against those strains. Antibodies induced by the polypeptides are also provided.Type: GrantFiled: July 8, 1997Date of Patent: July 18, 2000Assignee: Genentech, Inc.Inventor: Phillip W. Berman
-
Patent number: 6042836Abstract: A method for the rational design and preparation of vaccines based on HIV envelope polypeptides is described. In one embodiment, the method for making an HIV gp120 subunit vaccine for a geographic region comprises determining neutralizing epitopes in the V2 and/or C4 domains of gp120 of HIV isolates from the geographic region and selecting an HIV strain having gp120 a neutralizing epitope in the V2 or C4 domain which is common among isolates in the geographic region. In a preferred embodiment of the method, neutralizing epitopes for the V2, V3, and C4 domains of gp120 are determined. At least two HIV isolates having different neutralizing epitopes in the V2, V3, or C4 domain are selected and used to make the vaccine. The invention also provides a multivalent HIV gp120 subunit vaccine.Type: GrantFiled: August 13, 1998Date of Patent: March 28, 2000Assignee: Genentech, Inc.Inventors: Phillip W. Berman, Gerald R. Nakamura
-
Patent number: 5864027Abstract: A method for the rational design and preparation of vaccines based on HIV envelope polypeptides is described. In one embodiment, the method for making an HIV gp120 subunit vaccine for a geographic region comprises determining neutralizing epitopes in the V2 and/or C4 domains of gp120 of HIV as depicted in the figure. In a preferred embodiment of the method, neutralizing epitopes for the V2, V3 and C4 domains of gp120 are determined. Also described are DNA sequences encoding gp120 from preferred vaccine strains of HIV.Type: GrantFiled: October 10, 1995Date of Patent: January 26, 1999Assignee: Genentech, Inc.Inventors: Phillip W. Berman, Gerald R. Nakamura
-
Patent number: 5853978Abstract: Diagnostic product and vaccine for Acquired Immuno-deficiency Syndrome (AIDS) and methods for making and using same, wherein viral polypeptide sequences from an AIDS associated retrovirus are expressed directly or as a fusion polypeptide in a prokaryotic or mammalian cell expression host to produce a diagnostic product which specifically binds complementary antibody produced by individuals afflicted with AIDS or a vaccine against AIDS which confers resistance to infection by AIDS associated retrovirus. The reverse transcriptase of an AIDS associated retrovirus is used separately or in a whole cell assay to identify compounds which selectively inhibit retroviral reverse transcriptase.Type: GrantFiled: July 29, 1994Date of Patent: December 29, 1998Assignee: Genentech, Inc.Inventors: Phillip W. Berman, Daniel J. Capon, Laurence A. Lasky
-
Patent number: 5851533Abstract: Disclosed is an invention related to the preparation and use of vaccines against pathogenic organisms, such as herpes virus. The vaccines hereof are based upon the use of glycoproteins of the organism, that have been prepared via recombinant means, and preferably C-truncated versions thereof. These glycoproteins when incorporated into a vaccine composition afford protection against pathogenic challenge after administration.Type: GrantFiled: December 15, 1994Date of Patent: December 22, 1998Assignee: Genentech, Inc.Inventors: Phillip W. Berman, Laurence A. Lasky